{
    "nctId": "NCT00093834",
    "briefTitle": "Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer",
    "officialTitle": "A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by history and phys. exam. at 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Stage IV disease\n* Stable disease for \u2265 28 days\n* Measurable or evaluable disease OR no evidence of disease\n* Not eligible for potentially curative therapy\n* Adequately treated CNS metastases are allowed\n* Hormone receptor status:\n\n  * Not specified\n* HER-2/neu status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count \\> 1,000/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 2.0 mg/dL (unless due to Gilbert's syndrome)\n* AST and ALT \u2264 2 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 5 times ULN\n\nRenal\n\n* Creatinine \\< 2.0 mg/dL\n\nCardiovascular\n\n* Ejection fraction \u2265 45% by echocardiogram or MUGA\n\nPulmonary\n\n* Asthma or chronic obstructive pulmonary disease allowed provided daily systemic corticosteroid therapy is not required\n\nImmunologic\n\n* No active autoimmune disease requiring systemic immunosuppressive therapy, including any of the following:\n\n  * Inflammatory bowel disease\n  * Systemic vasculitis\n  * Scleroderma\n  * Psoriasis\n  * Multiple sclerosis\n  * Hemolytic anemia\n  * Immune-mediated thrombocytopenia\n  * Rheumatoid arthritis\n  * Systemic lupus erythematosus\n  * Sj\u00f6gren's syndrome\n  * Sarcoidosis\n  * Other rheumatologic disease\n* HIV negative\n* No active acute or chronic infection\n* No allergy to corn\n\nOther\n\n* No other malignancy within the past 5 years except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, or superficial bladder cancer\n* No active major medical or psychosocial problem that would preclude study participation\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* More than 28 days since prior biologic therapy\n* No other concurrent biologic therapy, including trastuzumab (Herceptin\u00ae)\n\nChemotherapy\n\n* Prior adjuvant chemotherapy allowed\n* Prior doxorubicin and cyclophosphamide allowed\n\n  * Prior doxorubicin dose combined with planned study therapy dose must not exceed a lifetime cumulative dose of \u2265 450 mg/m\\^2\n* More than 28 days since prior systemic chemotherapy\n* No other concurrent systemic chemotherapy\n\nEndocrine therapy\n\n* More than 28 days since prior systemic corticosteroids\n* Concurrent hormonal or endocrine therapy allowed\n\n  * No concurrent systemic corticosteroids\n\nRadiotherapy\n\n* More than 28 days since prior radiotherapy\n* No concurrent radiotherapy\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 28 days since prior participation in another investigational drug trial\n* No other concurrent investigational drugs\n* Concurrent bisphosphonates allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}